Global Measurable Residual Disease Testing Market Growth (Status and Outlook) 2026-2032
The global Measurable Residual Disease Testing market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Measurable residual disease (also known as “minimal residual disease”) refers to the number of cancer cells that remain during and after cancer treatment. Complete remission (less than 5% blasts in bone marrow) by morphologic assessment is not enough to accurately depict remaining malignant cells.
United States market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Measurable Residual Disease Testing players cover Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Measurable Residual Disease Testing Industry Forecast” looks at past sales and reviews total world Measurable Residual Disease Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Measurable Residual Disease Testing sales for 2026 through 2032. With Measurable Residual Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Measurable Residual Disease Testing industry.
This Insight Report provides a comprehensive analysis of the global Measurable Residual Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Measurable Residual Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Measurable Residual Disease Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Measurable Residual Disease Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Measurable Residual Disease Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Measurable Residual Disease Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
Measurable residual disease (also known as “minimal residual disease”) refers to the number of cancer cells that remain during and after cancer treatment. Complete remission (less than 5% blasts in bone marrow) by morphologic assessment is not enough to accurately depict remaining malignant cells.
United States market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Measurable Residual Disease Testing players cover Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Measurable Residual Disease Testing Industry Forecast” looks at past sales and reviews total world Measurable Residual Disease Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Measurable Residual Disease Testing sales for 2026 through 2032. With Measurable Residual Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Measurable Residual Disease Testing industry.
This Insight Report provides a comprehensive analysis of the global Measurable Residual Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Measurable Residual Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Measurable Residual Disease Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Measurable Residual Disease Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Measurable Residual Disease Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Measurable Residual Disease Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Other
- Hematological Malignancies
- Leukemia
- Lymphoma
- Solid Tumors
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Asuragen
- Arup Laboratories
- Bio-Rad Laboratories
- Cergentis B.V.
- F. Hoffmann- La Roche Ltd
- Guardant Health
- ICON plc
- Invivoscribe
- Laboratory Corporation of America Holdings
- Mission Bio
- Natera, Inc.
- NeoGenomics Laboratories
- Opko Health
- Quest Diagnostics Incorporated
- Sysmex Corporation
- Genetron Health
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Measurable Residual Disease Testing Market Size (2021-2032)
2.1.2 Measurable Residual Disease Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Measurable Residual Disease Testing by Country/Region (2021, 2025 & 2032)
2.2 Measurable Residual Disease Testing Segment by Type
2.2.1 Flow Cytometry
2.2.2 Polymerase Chain Reaction (PCR)
2.2.3 Next-Generation Sequencing (NGS)
2.2.4 Other
2.2.5 Measurable Residual Disease Testing Market Size by Type
2.2.5.1 Measurable Residual Disease Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
2.3 Measurable Residual Disease Testing Segment by Application
2.3.1 Hematological Malignancies
2.3.2 Leukemia
2.3.3 Lymphoma
2.3.4 Solid Tumors
2.3.5 Other
2.3.6 Measurable Residual Disease Testing Market Size by Application
2.3.6.1 Measurable Residual Disease Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.6.2 Global Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
3 MEASURABLE RESIDUAL DISEASE TESTING MARKET SIZE BY PLAYER
3.1 Measurable Residual Disease Testing Market Size Market Share by Player
3.1.1 Global Measurable Residual Disease Testing Revenue by Player (2021-2026)
3.1.2 Global Measurable Residual Disease Testing Revenue Market Share by Player (2021-2026)
3.2 Global Measurable Residual Disease Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 MEASURABLE RESIDUAL DISEASE TESTING BY REGION
4.1 Measurable Residual Disease Testing Market Size by Region (2021-2026)
4.2 Global Measurable Residual Disease Testing Annual Revenue by Country/Region (2021-2026)
4.3 Americas Measurable Residual Disease Testing Market Size Growth (2021-2026)
4.4 APAC Measurable Residual Disease Testing Market Size Growth (2021-2026)
4.5 Europe Measurable Residual Disease Testing Market Size Growth (2021-2026)
4.6 Middle East & Africa Measurable Residual Disease Testing Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Measurable Residual Disease Testing Market Size by Country (2021-2026)
5.2 Americas Measurable Residual Disease Testing Market Size by Type (2021-2026)
5.3 Americas Measurable Residual Disease Testing Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Measurable Residual Disease Testing Market Size by Region (2021-2026)
6.2 APAC Measurable Residual Disease Testing Market Size by Type (2021-2026)
6.3 APAC Measurable Residual Disease Testing Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Measurable Residual Disease Testing Market Size by Country (2021-2026)
7.2 Europe Measurable Residual Disease Testing Market Size by Type (2021-2026)
7.3 Europe Measurable Residual Disease Testing Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Measurable Residual Disease Testing by Region (2021-2026)
8.2 Middle East & Africa Measurable Residual Disease Testing Market Size by Type (2021-2026)
8.3 Middle East & Africa Measurable Residual Disease Testing Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL MEASURABLE RESIDUAL DISEASE TESTING MARKET FORECAST
10.1 Global Measurable Residual Disease Testing Forecast by Region (2027-2032)
10.1.1 Global Measurable Residual Disease Testing Forecast by Region (2027-2032)
10.1.2 Americas Measurable Residual Disease Testing Forecast
10.1.3 APAC Measurable Residual Disease Testing Forecast
10.1.4 Europe Measurable Residual Disease Testing Forecast
10.1.5 Middle East & Africa Measurable Residual Disease Testing Forecast
10.2 Americas Measurable Residual Disease Testing Forecast by Country (2027-2032)
10.2.1 United States Market Measurable Residual Disease Testing Forecast
10.2.2 Canada Market Measurable Residual Disease Testing Forecast
10.2.3 Mexico Market Measurable Residual Disease Testing Forecast
10.2.4 Brazil Market Measurable Residual Disease Testing Forecast
10.3 APAC Measurable Residual Disease Testing Forecast by Region (2027-2032)
10.3.1 China Measurable Residual Disease Testing Market Forecast
10.3.2 Japan Market Measurable Residual Disease Testing Forecast
10.3.3 Korea Market Measurable Residual Disease Testing Forecast
10.3.4 Southeast Asia Market Measurable Residual Disease Testing Forecast
10.3.5 India Market Measurable Residual Disease Testing Forecast
10.3.6 Australia Market Measurable Residual Disease Testing Forecast
10.4 Europe Measurable Residual Disease Testing Forecast by Country (2027-2032)
10.4.1 Germany Market Measurable Residual Disease Testing Forecast
10.4.2 France Market Measurable Residual Disease Testing Forecast
10.4.3 UK Market Measurable Residual Disease Testing Forecast
10.4.4 Italy Market Measurable Residual Disease Testing Forecast
10.4.5 Russia Market Measurable Residual Disease Testing Forecast
10.5 Middle East & Africa Measurable Residual Disease Testing Forecast by Region (2027-2032)
10.5.1 Egypt Market Measurable Residual Disease Testing Forecast
10.5.2 South Africa Market Measurable Residual Disease Testing Forecast
10.5.3 Israel Market Measurable Residual Disease Testing Forecast
10.5.4 Turkey Market Measurable Residual Disease Testing Forecast
10.6 Global Measurable Residual Disease Testing Forecast by Type (2027-2032)
10.7 Global Measurable Residual Disease Testing Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Measurable Residual Disease Testing Forecast
11 KEY PLAYERS ANALYSIS
11.1 Adaptive Biotechnologies Corporation
11.1.1 Adaptive Biotechnologies Corporation Company Information
11.1.2 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Product Offered
11.1.3 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Adaptive Biotechnologies Corporation Main Business Overview
11.1.5 Adaptive Biotechnologies Corporation Latest Developments
11.2 ArcherDX, Inc. (Invitae Corporation)
11.2.1 ArcherDX, Inc. (Invitae Corporation) Company Information
11.2.2 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Product Offered
11.2.3 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 ArcherDX, Inc. (Invitae Corporation) Main Business Overview
11.2.5 ArcherDX, Inc. (Invitae Corporation) Latest Developments
11.3 Asuragen
11.3.1 Asuragen Company Information
11.3.2 Asuragen Measurable Residual Disease Testing Product Offered
11.3.3 Asuragen Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Asuragen Main Business Overview
11.3.5 Asuragen Latest Developments
11.4 Arup Laboratories
11.4.1 Arup Laboratories Company Information
11.4.2 Arup Laboratories Measurable Residual Disease Testing Product Offered
11.4.3 Arup Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Arup Laboratories Main Business Overview
11.4.5 Arup Laboratories Latest Developments
11.5 Bio-Rad Laboratories
11.5.1 Bio-Rad Laboratories Company Information
11.5.2 Bio-Rad Laboratories Measurable Residual Disease Testing Product Offered
11.5.3 Bio-Rad Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Bio-Rad Laboratories Main Business Overview
11.5.5 Bio-Rad Laboratories Latest Developments
11.6 Cergentis B.V.
11.6.1 Cergentis B.V. Company Information
11.6.2 Cergentis B.V. Measurable Residual Disease Testing Product Offered
11.6.3 Cergentis B.V. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Cergentis B.V. Main Business Overview
11.6.5 Cergentis B.V. Latest Developments
11.7 F. Hoffmann- La Roche Ltd
11.7.1 F. Hoffmann- La Roche Ltd Company Information
11.7.2 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Product Offered
11.7.3 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 F. Hoffmann- La Roche Ltd Main Business Overview
11.7.5 F. Hoffmann- La Roche Ltd Latest Developments
11.8 Guardant Health
11.8.1 Guardant Health Company Information
11.8.2 Guardant Health Measurable Residual Disease Testing Product Offered
11.8.3 Guardant Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Guardant Health Main Business Overview
11.8.5 Guardant Health Latest Developments
11.9 ICON plc
11.9.1 ICON plc Company Information
11.9.2 ICON plc Measurable Residual Disease Testing Product Offered
11.9.3 ICON plc Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 ICON plc Main Business Overview
11.9.5 ICON plc Latest Developments
11.10 Invivoscribe
11.10.1 Invivoscribe Company Information
11.10.2 Invivoscribe Measurable Residual Disease Testing Product Offered
11.10.3 Invivoscribe Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Invivoscribe Main Business Overview
11.10.5 Invivoscribe Latest Developments
11.11 Laboratory Corporation of America Holdings
11.11.1 Laboratory Corporation of America Holdings Company Information
11.11.2 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Product Offered
11.11.3 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Laboratory Corporation of America Holdings Main Business Overview
11.11.5 Laboratory Corporation of America Holdings Latest Developments
11.12 Mission Bio
11.12.1 Mission Bio Company Information
11.12.2 Mission Bio Measurable Residual Disease Testing Product Offered
11.12.3 Mission Bio Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Mission Bio Main Business Overview
11.12.5 Mission Bio Latest Developments
11.13 Natera, Inc.
11.13.1 Natera, Inc. Company Information
11.13.2 Natera, Inc. Measurable Residual Disease Testing Product Offered
11.13.3 Natera, Inc. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Natera, Inc. Main Business Overview
11.13.5 Natera, Inc. Latest Developments
11.14 NeoGenomics Laboratories
11.14.1 NeoGenomics Laboratories Company Information
11.14.2 NeoGenomics Laboratories Measurable Residual Disease Testing Product Offered
11.14.3 NeoGenomics Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 NeoGenomics Laboratories Main Business Overview
11.14.5 NeoGenomics Laboratories Latest Developments
11.15 Opko Health
11.15.1 Opko Health Company Information
11.15.2 Opko Health Measurable Residual Disease Testing Product Offered
11.15.3 Opko Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Opko Health Main Business Overview
11.15.5 Opko Health Latest Developments
11.16 Quest Diagnostics Incorporated
11.16.1 Quest Diagnostics Incorporated Company Information
11.16.2 Quest Diagnostics Incorporated Measurable Residual Disease Testing Product Offered
11.16.3 Quest Diagnostics Incorporated Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Quest Diagnostics Incorporated Main Business Overview
11.16.5 Quest Diagnostics Incorporated Latest Developments
11.17 Sysmex Corporation
11.17.1 Sysmex Corporation Company Information
11.17.2 Sysmex Corporation Measurable Residual Disease Testing Product Offered
11.17.3 Sysmex Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sysmex Corporation Main Business Overview
11.17.5 Sysmex Corporation Latest Developments
11.18 Genetron Health
11.18.1 Genetron Health Company Information
11.18.2 Genetron Health Measurable Residual Disease Testing Product Offered
11.18.3 Genetron Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Genetron Health Main Business Overview
11.18.5 Genetron Health Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Measurable Residual Disease Testing Market Size (2021-2032)
2.1.2 Measurable Residual Disease Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Measurable Residual Disease Testing by Country/Region (2021, 2025 & 2032)
2.2 Measurable Residual Disease Testing Segment by Type
2.2.1 Flow Cytometry
2.2.2 Polymerase Chain Reaction (PCR)
2.2.3 Next-Generation Sequencing (NGS)
2.2.4 Other
2.2.5 Measurable Residual Disease Testing Market Size by Type
2.2.5.1 Measurable Residual Disease Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.5.2 Global Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
2.3 Measurable Residual Disease Testing Segment by Application
2.3.1 Hematological Malignancies
2.3.2 Leukemia
2.3.3 Lymphoma
2.3.4 Solid Tumors
2.3.5 Other
2.3.6 Measurable Residual Disease Testing Market Size by Application
2.3.6.1 Measurable Residual Disease Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.6.2 Global Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
3 MEASURABLE RESIDUAL DISEASE TESTING MARKET SIZE BY PLAYER
3.1 Measurable Residual Disease Testing Market Size Market Share by Player
3.1.1 Global Measurable Residual Disease Testing Revenue by Player (2021-2026)
3.1.2 Global Measurable Residual Disease Testing Revenue Market Share by Player (2021-2026)
3.2 Global Measurable Residual Disease Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 MEASURABLE RESIDUAL DISEASE TESTING BY REGION
4.1 Measurable Residual Disease Testing Market Size by Region (2021-2026)
4.2 Global Measurable Residual Disease Testing Annual Revenue by Country/Region (2021-2026)
4.3 Americas Measurable Residual Disease Testing Market Size Growth (2021-2026)
4.4 APAC Measurable Residual Disease Testing Market Size Growth (2021-2026)
4.5 Europe Measurable Residual Disease Testing Market Size Growth (2021-2026)
4.6 Middle East & Africa Measurable Residual Disease Testing Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Measurable Residual Disease Testing Market Size by Country (2021-2026)
5.2 Americas Measurable Residual Disease Testing Market Size by Type (2021-2026)
5.3 Americas Measurable Residual Disease Testing Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Measurable Residual Disease Testing Market Size by Region (2021-2026)
6.2 APAC Measurable Residual Disease Testing Market Size by Type (2021-2026)
6.3 APAC Measurable Residual Disease Testing Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Measurable Residual Disease Testing Market Size by Country (2021-2026)
7.2 Europe Measurable Residual Disease Testing Market Size by Type (2021-2026)
7.3 Europe Measurable Residual Disease Testing Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Measurable Residual Disease Testing by Region (2021-2026)
8.2 Middle East & Africa Measurable Residual Disease Testing Market Size by Type (2021-2026)
8.3 Middle East & Africa Measurable Residual Disease Testing Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL MEASURABLE RESIDUAL DISEASE TESTING MARKET FORECAST
10.1 Global Measurable Residual Disease Testing Forecast by Region (2027-2032)
10.1.1 Global Measurable Residual Disease Testing Forecast by Region (2027-2032)
10.1.2 Americas Measurable Residual Disease Testing Forecast
10.1.3 APAC Measurable Residual Disease Testing Forecast
10.1.4 Europe Measurable Residual Disease Testing Forecast
10.1.5 Middle East & Africa Measurable Residual Disease Testing Forecast
10.2 Americas Measurable Residual Disease Testing Forecast by Country (2027-2032)
10.2.1 United States Market Measurable Residual Disease Testing Forecast
10.2.2 Canada Market Measurable Residual Disease Testing Forecast
10.2.3 Mexico Market Measurable Residual Disease Testing Forecast
10.2.4 Brazil Market Measurable Residual Disease Testing Forecast
10.3 APAC Measurable Residual Disease Testing Forecast by Region (2027-2032)
10.3.1 China Measurable Residual Disease Testing Market Forecast
10.3.2 Japan Market Measurable Residual Disease Testing Forecast
10.3.3 Korea Market Measurable Residual Disease Testing Forecast
10.3.4 Southeast Asia Market Measurable Residual Disease Testing Forecast
10.3.5 India Market Measurable Residual Disease Testing Forecast
10.3.6 Australia Market Measurable Residual Disease Testing Forecast
10.4 Europe Measurable Residual Disease Testing Forecast by Country (2027-2032)
10.4.1 Germany Market Measurable Residual Disease Testing Forecast
10.4.2 France Market Measurable Residual Disease Testing Forecast
10.4.3 UK Market Measurable Residual Disease Testing Forecast
10.4.4 Italy Market Measurable Residual Disease Testing Forecast
10.4.5 Russia Market Measurable Residual Disease Testing Forecast
10.5 Middle East & Africa Measurable Residual Disease Testing Forecast by Region (2027-2032)
10.5.1 Egypt Market Measurable Residual Disease Testing Forecast
10.5.2 South Africa Market Measurable Residual Disease Testing Forecast
10.5.3 Israel Market Measurable Residual Disease Testing Forecast
10.5.4 Turkey Market Measurable Residual Disease Testing Forecast
10.6 Global Measurable Residual Disease Testing Forecast by Type (2027-2032)
10.7 Global Measurable Residual Disease Testing Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Measurable Residual Disease Testing Forecast
11 KEY PLAYERS ANALYSIS
11.1 Adaptive Biotechnologies Corporation
11.1.1 Adaptive Biotechnologies Corporation Company Information
11.1.2 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Product Offered
11.1.3 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Adaptive Biotechnologies Corporation Main Business Overview
11.1.5 Adaptive Biotechnologies Corporation Latest Developments
11.2 ArcherDX, Inc. (Invitae Corporation)
11.2.1 ArcherDX, Inc. (Invitae Corporation) Company Information
11.2.2 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Product Offered
11.2.3 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 ArcherDX, Inc. (Invitae Corporation) Main Business Overview
11.2.5 ArcherDX, Inc. (Invitae Corporation) Latest Developments
11.3 Asuragen
11.3.1 Asuragen Company Information
11.3.2 Asuragen Measurable Residual Disease Testing Product Offered
11.3.3 Asuragen Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Asuragen Main Business Overview
11.3.5 Asuragen Latest Developments
11.4 Arup Laboratories
11.4.1 Arup Laboratories Company Information
11.4.2 Arup Laboratories Measurable Residual Disease Testing Product Offered
11.4.3 Arup Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Arup Laboratories Main Business Overview
11.4.5 Arup Laboratories Latest Developments
11.5 Bio-Rad Laboratories
11.5.1 Bio-Rad Laboratories Company Information
11.5.2 Bio-Rad Laboratories Measurable Residual Disease Testing Product Offered
11.5.3 Bio-Rad Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Bio-Rad Laboratories Main Business Overview
11.5.5 Bio-Rad Laboratories Latest Developments
11.6 Cergentis B.V.
11.6.1 Cergentis B.V. Company Information
11.6.2 Cergentis B.V. Measurable Residual Disease Testing Product Offered
11.6.3 Cergentis B.V. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Cergentis B.V. Main Business Overview
11.6.5 Cergentis B.V. Latest Developments
11.7 F. Hoffmann- La Roche Ltd
11.7.1 F. Hoffmann- La Roche Ltd Company Information
11.7.2 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Product Offered
11.7.3 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 F. Hoffmann- La Roche Ltd Main Business Overview
11.7.5 F. Hoffmann- La Roche Ltd Latest Developments
11.8 Guardant Health
11.8.1 Guardant Health Company Information
11.8.2 Guardant Health Measurable Residual Disease Testing Product Offered
11.8.3 Guardant Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Guardant Health Main Business Overview
11.8.5 Guardant Health Latest Developments
11.9 ICON plc
11.9.1 ICON plc Company Information
11.9.2 ICON plc Measurable Residual Disease Testing Product Offered
11.9.3 ICON plc Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 ICON plc Main Business Overview
11.9.5 ICON plc Latest Developments
11.10 Invivoscribe
11.10.1 Invivoscribe Company Information
11.10.2 Invivoscribe Measurable Residual Disease Testing Product Offered
11.10.3 Invivoscribe Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Invivoscribe Main Business Overview
11.10.5 Invivoscribe Latest Developments
11.11 Laboratory Corporation of America Holdings
11.11.1 Laboratory Corporation of America Holdings Company Information
11.11.2 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Product Offered
11.11.3 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Laboratory Corporation of America Holdings Main Business Overview
11.11.5 Laboratory Corporation of America Holdings Latest Developments
11.12 Mission Bio
11.12.1 Mission Bio Company Information
11.12.2 Mission Bio Measurable Residual Disease Testing Product Offered
11.12.3 Mission Bio Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Mission Bio Main Business Overview
11.12.5 Mission Bio Latest Developments
11.13 Natera, Inc.
11.13.1 Natera, Inc. Company Information
11.13.2 Natera, Inc. Measurable Residual Disease Testing Product Offered
11.13.3 Natera, Inc. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Natera, Inc. Main Business Overview
11.13.5 Natera, Inc. Latest Developments
11.14 NeoGenomics Laboratories
11.14.1 NeoGenomics Laboratories Company Information
11.14.2 NeoGenomics Laboratories Measurable Residual Disease Testing Product Offered
11.14.3 NeoGenomics Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 NeoGenomics Laboratories Main Business Overview
11.14.5 NeoGenomics Laboratories Latest Developments
11.15 Opko Health
11.15.1 Opko Health Company Information
11.15.2 Opko Health Measurable Residual Disease Testing Product Offered
11.15.3 Opko Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Opko Health Main Business Overview
11.15.5 Opko Health Latest Developments
11.16 Quest Diagnostics Incorporated
11.16.1 Quest Diagnostics Incorporated Company Information
11.16.2 Quest Diagnostics Incorporated Measurable Residual Disease Testing Product Offered
11.16.3 Quest Diagnostics Incorporated Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Quest Diagnostics Incorporated Main Business Overview
11.16.5 Quest Diagnostics Incorporated Latest Developments
11.17 Sysmex Corporation
11.17.1 Sysmex Corporation Company Information
11.17.2 Sysmex Corporation Measurable Residual Disease Testing Product Offered
11.17.3 Sysmex Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sysmex Corporation Main Business Overview
11.17.5 Sysmex Corporation Latest Developments
11.18 Genetron Health
11.18.1 Genetron Health Company Information
11.18.2 Genetron Health Measurable Residual Disease Testing Product Offered
11.18.3 Genetron Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Genetron Health Main Business Overview
11.18.5 Genetron Health Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Measurable Residual Disease Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Measurable Residual Disease Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Flow Cytometry
Table 4. Major Players of Polymerase Chain Reaction (PCR)
Table 5. Major Players of Next-Generation Sequencing (NGS)
Table 6. Major Players of Other
Table 7. Measurable Residual Disease Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Measurable Residual Disease Testing Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
Table 10. Measurable Residual Disease Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Measurable Residual Disease Testing Market Size by Application (2021-2026) & ($ millions)
Table 12. Global Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
Table 13. Global Measurable Residual Disease Testing Revenue by Player (2021-2026) & ($ millions)
Table 14. Global Measurable Residual Disease Testing Revenue Market Share by Player (2021-2026)
Table 15. Measurable Residual Disease Testing Key Players Head office and Products Offered
Table 16. Measurable Residual Disease Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Measurable Residual Disease Testing Market Size by Region (2021-2026) & ($ millions)
Table 20. Global Measurable Residual Disease Testing Market Size Market Share by Region (2021-2026)
Table 21. Global Measurable Residual Disease Testing Revenue by Country/Region (2021-2026) & ($ millions)
Table 22. Global Measurable Residual Disease Testing Revenue Market Share by Country/Region (2021-2026)
Table 23. Americas Measurable Residual Disease Testing Market Size by Country (2021-2026) & ($ millions)
Table 24. Americas Measurable Residual Disease Testing Market Size Market Share by Country (2021-2026)
Table 25. Americas Measurable Residual Disease Testing Market Size by Type (2021-2026) & ($ millions)
Table 26. Americas Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
Table 27. Americas Measurable Residual Disease Testing Market Size by Application (2021-2026) & ($ millions)
Table 28. Americas Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
Table 29. APAC Measurable Residual Disease Testing Market Size by Region (2021-2026) & ($ millions)
Table 30. APAC Measurable Residual Disease Testing Market Size Market Share by Region (2021-2026)
Table 31. APAC Measurable Residual Disease Testing Market Size by Type (2021-2026) & ($ millions)
Table 32. APAC Measurable Residual Disease Testing Market Size by Application (2021-2026) & ($ millions)
Table 33. Europe Measurable Residual Disease Testing Market Size by Country (2021-2026) & ($ millions)
Table 34. Europe Measurable Residual Disease Testing Market Size Market Share by Country (2021-2026)
Table 35. Europe Measurable Residual Disease Testing Market Size by Type (2021-2026) & ($ millions)
Table 36. Europe Measurable Residual Disease Testing Market Size by Application (2021-2026) & ($ millions)
Table 37. Middle East & Africa Measurable Residual Disease Testing Market Size by Region (2021-2026) & ($ millions)
Table 38. Middle East & Africa Measurable Residual Disease Testing Market Size by Type (2021-2026) & ($ millions)
Table 39. Middle East & Africa Measurable Residual Disease Testing Market Size by Application (2021-2026) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Measurable Residual Disease Testing
Table 41. Key Market Challenges & Risks of Measurable Residual Disease Testing
Table 42. Key Industry Trends of Measurable Residual Disease Testing
Table 43. Global Measurable Residual Disease Testing Market Size Forecast by Region (2027-2032) & ($ millions)
Table 44. Global Measurable Residual Disease Testing Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global Measurable Residual Disease Testing Market Size Forecast by Type (2027-2032) & ($ millions)
Table 46. Global Measurable Residual Disease Testing Market Size Forecast by Application (2027-2032) & ($ millions)
Table 47. Adaptive Biotechnologies Corporation Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 48. Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Product Offered
Table 49. Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 50. Adaptive Biotechnologies Corporation Main Business
Table 51. Adaptive Biotechnologies Corporation Latest Developments
Table 52. ArcherDX, Inc. (Invitae Corporation) Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 53. ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Product Offered
Table 54. ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 55. ArcherDX, Inc. (Invitae Corporation) Main Business
Table 56. ArcherDX, Inc. (Invitae Corporation) Latest Developments
Table 57. Asuragen Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 58. Asuragen Measurable Residual Disease Testing Product Offered
Table 59. Asuragen Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Asuragen Main Business
Table 61. Asuragen Latest Developments
Table 62. Arup Laboratories Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 63. Arup Laboratories Measurable Residual Disease Testing Product Offered
Table 64. Arup Laboratories Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Arup Laboratories Main Business
Table 66. Arup Laboratories Latest Developments
Table 67. Bio-Rad Laboratories Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 68. Bio-Rad Laboratories Measurable Residual Disease Testing Product Offered
Table 69. Bio-Rad Laboratories Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Bio-Rad Laboratories Main Business
Table 71. Bio-Rad Laboratories Latest Developments
Table 72. Cergentis B.V. Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 73. Cergentis B.V. Measurable Residual Disease Testing Product Offered
Table 74. Cergentis B.V. Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Cergentis B.V. Main Business
Table 76. Cergentis B.V. Latest Developments
Table 77. F. Hoffmann- La Roche Ltd Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 78. F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Product Offered
Table 79. F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. F. Hoffmann- La Roche Ltd Main Business
Table 81. F. Hoffmann- La Roche Ltd Latest Developments
Table 82. Guardant Health Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 83. Guardant Health Measurable Residual Disease Testing Product Offered
Table 84. Guardant Health Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Guardant Health Main Business
Table 86. Guardant Health Latest Developments
Table 87. ICON plc Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 88. ICON plc Measurable Residual Disease Testing Product Offered
Table 89. ICON plc Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. ICON plc Main Business
Table 91. ICON plc Latest Developments
Table 92. Invivoscribe Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 93. Invivoscribe Measurable Residual Disease Testing Product Offered
Table 94. Invivoscribe Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Invivoscribe Main Business
Table 96. Invivoscribe Latest Developments
Table 97. Laboratory Corporation of America Holdings Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 98. Laboratory Corporation of America Holdings Measurable Residual Disease Testing Product Offered
Table 99. Laboratory Corporation of America Holdings Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Laboratory Corporation of America Holdings Main Business
Table 101. Laboratory Corporation of America Holdings Latest Developments
Table 102. Mission Bio Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 103. Mission Bio Measurable Residual Disease Testing Product Offered
Table 104. Mission Bio Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Mission Bio Main Business
Table 106. Mission Bio Latest Developments
Table 107. Natera, Inc. Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 108. Natera, Inc. Measurable Residual Disease Testing Product Offered
Table 109. Natera, Inc. Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Natera, Inc. Main Business
Table 111. Natera, Inc. Latest Developments
Table 112. NeoGenomics Laboratories Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 113. NeoGenomics Laboratories Measurable Residual Disease Testing Product Offered
Table 114. NeoGenomics Laboratories Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. NeoGenomics Laboratories Main Business
Table 116. NeoGenomics Laboratories Latest Developments
Table 117. Opko Health Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 118. Opko Health Measurable Residual Disease Testing Product Offered
Table 119. Opko Health Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 120. Opko Health Main Business
Table 121. Opko Health Latest Developments
Table 122. Quest Diagnostics Incorporated Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 123. Quest Diagnostics Incorporated Measurable Residual Disease Testing Product Offered
Table 124. Quest Diagnostics Incorporated Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 125. Quest Diagnostics Incorporated Main Business
Table 126. Quest Diagnostics Incorporated Latest Developments
Table 127. Sysmex Corporation Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 128. Sysmex Corporation Measurable Residual Disease Testing Product Offered
Table 129. Sysmex Corporation Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 130. Sysmex Corporation Main Business
Table 131. Sysmex Corporation Latest Developments
Table 132. Genetron Health Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 133. Genetron Health Measurable Residual Disease Testing Product Offered
Table 134. Genetron Health Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 135. Genetron Health Main Business
Table 136. Genetron Health Latest Developments
Table 1. Measurable Residual Disease Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Measurable Residual Disease Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Flow Cytometry
Table 4. Major Players of Polymerase Chain Reaction (PCR)
Table 5. Major Players of Next-Generation Sequencing (NGS)
Table 6. Major Players of Other
Table 7. Measurable Residual Disease Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 8. Global Measurable Residual Disease Testing Market Size by Type (2021-2026) & ($ millions)
Table 9. Global Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
Table 10. Measurable Residual Disease Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 11. Global Measurable Residual Disease Testing Market Size by Application (2021-2026) & ($ millions)
Table 12. Global Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
Table 13. Global Measurable Residual Disease Testing Revenue by Player (2021-2026) & ($ millions)
Table 14. Global Measurable Residual Disease Testing Revenue Market Share by Player (2021-2026)
Table 15. Measurable Residual Disease Testing Key Players Head office and Products Offered
Table 16. Measurable Residual Disease Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Measurable Residual Disease Testing Market Size by Region (2021-2026) & ($ millions)
Table 20. Global Measurable Residual Disease Testing Market Size Market Share by Region (2021-2026)
Table 21. Global Measurable Residual Disease Testing Revenue by Country/Region (2021-2026) & ($ millions)
Table 22. Global Measurable Residual Disease Testing Revenue Market Share by Country/Region (2021-2026)
Table 23. Americas Measurable Residual Disease Testing Market Size by Country (2021-2026) & ($ millions)
Table 24. Americas Measurable Residual Disease Testing Market Size Market Share by Country (2021-2026)
Table 25. Americas Measurable Residual Disease Testing Market Size by Type (2021-2026) & ($ millions)
Table 26. Americas Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
Table 27. Americas Measurable Residual Disease Testing Market Size by Application (2021-2026) & ($ millions)
Table 28. Americas Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
Table 29. APAC Measurable Residual Disease Testing Market Size by Region (2021-2026) & ($ millions)
Table 30. APAC Measurable Residual Disease Testing Market Size Market Share by Region (2021-2026)
Table 31. APAC Measurable Residual Disease Testing Market Size by Type (2021-2026) & ($ millions)
Table 32. APAC Measurable Residual Disease Testing Market Size by Application (2021-2026) & ($ millions)
Table 33. Europe Measurable Residual Disease Testing Market Size by Country (2021-2026) & ($ millions)
Table 34. Europe Measurable Residual Disease Testing Market Size Market Share by Country (2021-2026)
Table 35. Europe Measurable Residual Disease Testing Market Size by Type (2021-2026) & ($ millions)
Table 36. Europe Measurable Residual Disease Testing Market Size by Application (2021-2026) & ($ millions)
Table 37. Middle East & Africa Measurable Residual Disease Testing Market Size by Region (2021-2026) & ($ millions)
Table 38. Middle East & Africa Measurable Residual Disease Testing Market Size by Type (2021-2026) & ($ millions)
Table 39. Middle East & Africa Measurable Residual Disease Testing Market Size by Application (2021-2026) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Measurable Residual Disease Testing
Table 41. Key Market Challenges & Risks of Measurable Residual Disease Testing
Table 42. Key Industry Trends of Measurable Residual Disease Testing
Table 43. Global Measurable Residual Disease Testing Market Size Forecast by Region (2027-2032) & ($ millions)
Table 44. Global Measurable Residual Disease Testing Market Size Market Share Forecast by Region (2027-2032)
Table 45. Global Measurable Residual Disease Testing Market Size Forecast by Type (2027-2032) & ($ millions)
Table 46. Global Measurable Residual Disease Testing Market Size Forecast by Application (2027-2032) & ($ millions)
Table 47. Adaptive Biotechnologies Corporation Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 48. Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Product Offered
Table 49. Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 50. Adaptive Biotechnologies Corporation Main Business
Table 51. Adaptive Biotechnologies Corporation Latest Developments
Table 52. ArcherDX, Inc. (Invitae Corporation) Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 53. ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Product Offered
Table 54. ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 55. ArcherDX, Inc. (Invitae Corporation) Main Business
Table 56. ArcherDX, Inc. (Invitae Corporation) Latest Developments
Table 57. Asuragen Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 58. Asuragen Measurable Residual Disease Testing Product Offered
Table 59. Asuragen Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 60. Asuragen Main Business
Table 61. Asuragen Latest Developments
Table 62. Arup Laboratories Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 63. Arup Laboratories Measurable Residual Disease Testing Product Offered
Table 64. Arup Laboratories Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 65. Arup Laboratories Main Business
Table 66. Arup Laboratories Latest Developments
Table 67. Bio-Rad Laboratories Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 68. Bio-Rad Laboratories Measurable Residual Disease Testing Product Offered
Table 69. Bio-Rad Laboratories Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 70. Bio-Rad Laboratories Main Business
Table 71. Bio-Rad Laboratories Latest Developments
Table 72. Cergentis B.V. Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 73. Cergentis B.V. Measurable Residual Disease Testing Product Offered
Table 74. Cergentis B.V. Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 75. Cergentis B.V. Main Business
Table 76. Cergentis B.V. Latest Developments
Table 77. F. Hoffmann- La Roche Ltd Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 78. F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Product Offered
Table 79. F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 80. F. Hoffmann- La Roche Ltd Main Business
Table 81. F. Hoffmann- La Roche Ltd Latest Developments
Table 82. Guardant Health Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 83. Guardant Health Measurable Residual Disease Testing Product Offered
Table 84. Guardant Health Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 85. Guardant Health Main Business
Table 86. Guardant Health Latest Developments
Table 87. ICON plc Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 88. ICON plc Measurable Residual Disease Testing Product Offered
Table 89. ICON plc Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 90. ICON plc Main Business
Table 91. ICON plc Latest Developments
Table 92. Invivoscribe Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 93. Invivoscribe Measurable Residual Disease Testing Product Offered
Table 94. Invivoscribe Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 95. Invivoscribe Main Business
Table 96. Invivoscribe Latest Developments
Table 97. Laboratory Corporation of America Holdings Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 98. Laboratory Corporation of America Holdings Measurable Residual Disease Testing Product Offered
Table 99. Laboratory Corporation of America Holdings Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 100. Laboratory Corporation of America Holdings Main Business
Table 101. Laboratory Corporation of America Holdings Latest Developments
Table 102. Mission Bio Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 103. Mission Bio Measurable Residual Disease Testing Product Offered
Table 104. Mission Bio Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 105. Mission Bio Main Business
Table 106. Mission Bio Latest Developments
Table 107. Natera, Inc. Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 108. Natera, Inc. Measurable Residual Disease Testing Product Offered
Table 109. Natera, Inc. Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 110. Natera, Inc. Main Business
Table 111. Natera, Inc. Latest Developments
Table 112. NeoGenomics Laboratories Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 113. NeoGenomics Laboratories Measurable Residual Disease Testing Product Offered
Table 114. NeoGenomics Laboratories Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 115. NeoGenomics Laboratories Main Business
Table 116. NeoGenomics Laboratories Latest Developments
Table 117. Opko Health Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 118. Opko Health Measurable Residual Disease Testing Product Offered
Table 119. Opko Health Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 120. Opko Health Main Business
Table 121. Opko Health Latest Developments
Table 122. Quest Diagnostics Incorporated Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 123. Quest Diagnostics Incorporated Measurable Residual Disease Testing Product Offered
Table 124. Quest Diagnostics Incorporated Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 125. Quest Diagnostics Incorporated Main Business
Table 126. Quest Diagnostics Incorporated Latest Developments
Table 127. Sysmex Corporation Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 128. Sysmex Corporation Measurable Residual Disease Testing Product Offered
Table 129. Sysmex Corporation Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 130. Sysmex Corporation Main Business
Table 131. Sysmex Corporation Latest Developments
Table 132. Genetron Health Details, Company Type, Measurable Residual Disease Testing Area Served and Its Competitors
Table 133. Genetron Health Measurable Residual Disease Testing Product Offered
Table 134. Genetron Health Measurable Residual Disease Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 135. Genetron Health Main Business
Table 136. Genetron Health Latest Developments
LIST OF FIGURES
Figure 1. Measurable Residual Disease Testing Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Measurable Residual Disease Testing Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Measurable Residual Disease Testing Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Measurable Residual Disease Testing Sales Market Share by Country/Region (2025)
Figure 8. Measurable Residual Disease Testing Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Measurable Residual Disease Testing Market Size Market Share by Type in 2025
Figure 10. Measurable Residual Disease Testing in Hematological Malignancies
Figure 11. Global Measurable Residual Disease Testing Market: Hematological Malignancies (2021-2026) & ($ millions)
Figure 12. Measurable Residual Disease Testing in Leukemia
Figure 13. Global Measurable Residual Disease Testing Market: Leukemia (2021-2026) & ($ millions)
Figure 14. Measurable Residual Disease Testing in Lymphoma
Figure 15. Global Measurable Residual Disease Testing Market: Lymphoma (2021-2026) & ($ millions)
Figure 16. Measurable Residual Disease Testing in Solid Tumors
Figure 17. Global Measurable Residual Disease Testing Market: Solid Tumors (2021-2026) & ($ millions)
Figure 18. Measurable Residual Disease Testing in Other
Figure 19. Global Measurable Residual Disease Testing Market: Other (2021-2026) & ($ millions)
Figure 20. Global Measurable Residual Disease Testing Market Size Market Share by Application in 2025
Figure 21. Global Measurable Residual Disease Testing Revenue Market Share by Player in 2025
Figure 22. Global Measurable Residual Disease Testing Market Size Market Share by Region (2021-2026)
Figure 23. Americas Measurable Residual Disease Testing Market Size 2021-2026 ($ millions)
Figure 24. APAC Measurable Residual Disease Testing Market Size 2021-2026 ($ millions)
Figure 25. Europe Measurable Residual Disease Testing Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa Measurable Residual Disease Testing Market Size 2021-2026 ($ millions)
Figure 27. Americas Measurable Residual Disease Testing Value Market Share by Country in 2025
Figure 28. United States Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC Measurable Residual Disease Testing Market Size Market Share by Region in 2025
Figure 33. APAC Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
Figure 34. APAC Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
Figure 35. China Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 39. India Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe Measurable Residual Disease Testing Market Size Market Share by Country in 2025
Figure 42. Europe Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
Figure 43. Europe Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
Figure 44. Germany Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 45. France Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 46. UK Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa Measurable Residual Disease Testing Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
Figure 52. Egypt Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 58. APAC Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 59. Europe Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 61. United States Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 62. Canada Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 63. Mexico Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 64. Brazil Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 65. China Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 66. Japan Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 67. Korea Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 69. India Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 70. Australia Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 71. Germany Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 72. France Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 73. UK Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 74. Italy Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 75. Russia Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 76. Egypt Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 77. South Africa Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 78. Israel Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 79. Turkey Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 80. Global Measurable Residual Disease Testing Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global Measurable Residual Disease Testing Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 1. Measurable Residual Disease Testing Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Measurable Residual Disease Testing Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Measurable Residual Disease Testing Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Measurable Residual Disease Testing Sales Market Share by Country/Region (2025)
Figure 8. Measurable Residual Disease Testing Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Measurable Residual Disease Testing Market Size Market Share by Type in 2025
Figure 10. Measurable Residual Disease Testing in Hematological Malignancies
Figure 11. Global Measurable Residual Disease Testing Market: Hematological Malignancies (2021-2026) & ($ millions)
Figure 12. Measurable Residual Disease Testing in Leukemia
Figure 13. Global Measurable Residual Disease Testing Market: Leukemia (2021-2026) & ($ millions)
Figure 14. Measurable Residual Disease Testing in Lymphoma
Figure 15. Global Measurable Residual Disease Testing Market: Lymphoma (2021-2026) & ($ millions)
Figure 16. Measurable Residual Disease Testing in Solid Tumors
Figure 17. Global Measurable Residual Disease Testing Market: Solid Tumors (2021-2026) & ($ millions)
Figure 18. Measurable Residual Disease Testing in Other
Figure 19. Global Measurable Residual Disease Testing Market: Other (2021-2026) & ($ millions)
Figure 20. Global Measurable Residual Disease Testing Market Size Market Share by Application in 2025
Figure 21. Global Measurable Residual Disease Testing Revenue Market Share by Player in 2025
Figure 22. Global Measurable Residual Disease Testing Market Size Market Share by Region (2021-2026)
Figure 23. Americas Measurable Residual Disease Testing Market Size 2021-2026 ($ millions)
Figure 24. APAC Measurable Residual Disease Testing Market Size 2021-2026 ($ millions)
Figure 25. Europe Measurable Residual Disease Testing Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa Measurable Residual Disease Testing Market Size 2021-2026 ($ millions)
Figure 27. Americas Measurable Residual Disease Testing Value Market Share by Country in 2025
Figure 28. United States Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC Measurable Residual Disease Testing Market Size Market Share by Region in 2025
Figure 33. APAC Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
Figure 34. APAC Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
Figure 35. China Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 39. India Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe Measurable Residual Disease Testing Market Size Market Share by Country in 2025
Figure 42. Europe Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
Figure 43. Europe Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
Figure 44. Germany Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 45. France Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 46. UK Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa Measurable Residual Disease Testing Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa Measurable Residual Disease Testing Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa Measurable Residual Disease Testing Market Size Market Share by Application (2021-2026)
Figure 52. Egypt Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries Measurable Residual Disease Testing Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 58. APAC Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 59. Europe Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 61. United States Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 62. Canada Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 63. Mexico Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 64. Brazil Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 65. China Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 66. Japan Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 67. Korea Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 69. India Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 70. Australia Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 71. Germany Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 72. France Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 73. UK Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 74. Italy Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 75. Russia Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 76. Egypt Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 77. South Africa Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 78. Israel Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 79. Turkey Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
Figure 80. Global Measurable Residual Disease Testing Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global Measurable Residual Disease Testing Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries Measurable Residual Disease Testing Market Size 2027-2032 ($ millions)
